Synonyms: | |
Status: | Phase 2 |
Entry Type: | Small molecule |
Molecule Category: | UNKNOWN |
UNII: | F2DQF16BXE |
InChI Key | KKYABQBFGDZVNQ-UHFFFAOYSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C22H26FN3O2 |
Molecular Weight | 383.47 |
AlogP | 3.86 |
Hydrogen Bond Acceptor | 3.0 |
Hydrogen Bond Donor | 2.0 |
Number of Rotational Bond | 5.0 |
Polar Surface Area | 71.09 |
Molecular species | NEUTRAL |
Aromatic Rings | 2.0 |
Heavy Atoms | 28.0 |
Primary Target | |
---|---|
mitogen-activated protein kinase 14 |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Cytochrome P450
Cytochrome P450 family 2
Cytochrome P450 family 2C
Cytochrome P450 2C9
|
- | 31623 | - | - | - | |
Enzyme
Kinase
Protein Kinase
CMGC protein kinase group
CMGC protein kinase MAPK family
CMGC protein kinase p38 subfamily
|
- | 25-100 | - | 8-63 | - |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Acute Coronary Syndrome | 3 | D054058 | ClinicalTrials |
Severe Acute Respiratory Syndrome | 3 | D045169 | ClinicalTrials |
Neuralgia | 2 | D009437 | ClinicalTrials |
Glomerulosclerosis, Focal Segmental | 2 | D005923 | ClinicalTrials |
Pulmonary Disease, Chronic Obstructive | 2 | D029424 | ClinicalTrials |
Atherosclerosis | 2 | D050197 | ClinicalTrials |
Arthritis, Rheumatoid | 2 | D001172 | ClinicalTrials |
Lipid Metabolism Disorders | 2 | D052439 | ClinicalTrials |
Muscular Dystrophy, Facioscapulohumeral | 2 | D020391 | ClinicalTrials |
Depressive Disorder, Major | 2 | D003865 | ClinicalTrials |
Cardiovascular Diseases | 1 | D002318 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 585543-15-3 |
ChEBI | 131167 |
ChEMBL | CHEMBL1088752 |
DrugBank | DB12270 |
FDA SRS | F2DQF16BXE |
Guide to Pharmacology | 7835 |
PubChem | 11552706 |
SureChEMBL | SCHEMBL1070401 |
ZINC | ZINC000035793138 |